Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Mise à jour : Il y a 4 ans
Référence : NCT01738360

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary objectives : - To investigate the safety and the tolerability of ATO by IV infusions to patients with SLE, - To determine the maximum tolerated dose of ATO. Secondary objectives : - Evaluation of the clinical and biological response of the SLE to ATO, - Time of relapse in case of positive response, - Determination of the efficacy, - Pharmacokinetic study of ATO.


Critère d'inclusion

  • Systemic Lupus

Liens